Log in to save to my catalogue
Log in to save to my catalogue

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mut...

| Ask | Become a Library member

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mut...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2465718235

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

About this item

Full title

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Author / Creator

Zhong, Wen-Zhao, Prof , Wang, Qun, Prof , Mao, Wei-Min, Prof , Xu, Song-Tao, Prof , Wu, Lin, Prof , Shen, Yi, Prof , Liu, Yong-Yu, Prof , Chen, Chun, Prof , Cheng, Ying, Prof , Xu, Lin, Prof , Wang, Jun, Prof , Fei, Ke, Prof , Li, Xiao-Fei, Prof , Li, Jian, Prof , Huang, Cheng, Prof , Liu, Zhi-Dong, Prof , Xu, Shun, Prof , Chen, Ke-Neng, Prof , Xu, Shi-Dong, Prof , Liu, Lun-Xu, Prof , Yu, Ping, Prof , Wang, Bu-Hai, Prof , Ma, Hai-Tao, Prof , Yan, Hong-Hong, MD , Yang, Xue-Ning, Prof , Zhou, Qing, Prof , Wu, Yi-Long, Prof and ADJUVANT investigators

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2018, Vol.19 (1), p.139-148

Language

English

Formats

Articles

Publication information

Publisher

England: Elsevier Ltd

Subjects

Subjects and topics

More information

Scope and Contents

Contents

SummaryBackgroundCisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data suggest patients with EGFR-mutant stage IB–IIIA resected NSCLC could benefit from adjuvant EGFR tyrosine kinase inhibitor treatment. We aimed to compare the efficac...

Alternative Titles

Full title

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Authors, Artists and Contributors

Author / Creator

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2465718235

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2465718235

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(17)30729-5

How to access this item

Log in as a Library member

Full text available

About resource

View in old catalogue

Connecting people and collections